EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
NOVATO, Calif., Sept. 16, 2016 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, September 19 at 11am ET during which Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President, will discuss results of the KRN23 studies being presented at the American Society for Bone and Mineral Research (ASBMR) 2016 Annual Meeting.
The live and replayed webcast of the call will be available through the company's website at http://ir.ultragenyx.com/events.cfm. To participate in the live call by phone, dial 855-797-6910 (USA) or 262-912-6260 (international) and enter the passcode 83882106. The replay of the call will be available for one year.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273
